论文部分内容阅读
目的:观察静脉滴注人免疫球蛋白(IHIG)辅助治疗重症肺炎的疗效。方法:调查入住我院呼吸科的重症肺炎患者共84例,治疗组44例,对照组40例。2组均给予常规吸氧、排痰、抗感染等基础治疗。治疗组患者分为A、B亚组,分别在常规治疗的基部感染评分(CPIS)软件计分,评估患者的感染严重程度并比较用药前、后的分值变化情况与疗效的联系。结果:治疗组的咳嗽咳痰缓解时间、痰菌转阴时间均较对照组缩短,有效率为63.6%,明显好于对照组(32.5%,P<0.05)。治疗A组的X线胸片炎症吸收时间与对照组相比无显著性差异(P>0.05),但治疗B组与对照组比较,差异有统计学意义(P<0.05)。治疗组在应用IHIG后CPIS平均分值较应用前显著降低(P<0.05)。提示用药前、后的CPIS分值变化与疗效联系紧密。结论I:HIG辅助治疗重症肺炎疗效显著,可以预防炎症失控,降低死亡率。
Objective: To observe the effect of intravenous infusion of human immunoglobulin (IHIG) adjuvant therapy for severe pneumonia. Methods: A total of 84 patients with severe pneumonia were admitted to our department of respiratory department, 44 in the treatment group and 40 in the control group. Both groups were given conventional oxygen, expectoration, anti-infective and other basic treatment. The patients in the treatment group were divided into A and B subgroups. The patients were scored on the basis of routine treatment of the base infection score (CPIS) software to evaluate the severity of the infection and to compare the scores before and after treatment. Results: The cough and sputum remission time and sputum negative conversion time in the treatment group were shorter than those in the control group. The effective rate was 63.6%, which was significantly better than that of the control group (32.5%, P <0.05). There was no significant difference between the two groups (P> 0.05), but there was significant difference between treatment group B and control group (P <0.05). The mean score of CPIS in the treatment group after application of IHIG was significantly lower than that before application (P <0.05). Prompt medication before and after changes in the value of CPIS and efficacy are closely linked. Conclusions I: HIG adjuvant therapy for severe pneumonia has significant curative effect and can prevent uncontrollable inflammation and reduce mortality.